GlassScriptPhysician profile
Rama C Mulpuri
NPI 1366439697
$2,654.09
in general payments reported to CMS, 2019-2025
26 companies · $664 in 2025
The $664 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $474 · 2020: $465 · 2022: $68.28 · 2023: $329 · 2024: $653 · 2025: $664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,527 · Education: $90.00 · Long Term Medical Supply Or Device Loan: $29.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,526.58 |
| Education | $90.00 |
| Long Term Medical Supply Or Device Loan | $29.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $461.31 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $460.29 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $243.20 | 2019-2025 | Farxiga, Breztri |
| Pfizer INC. | $177.16 | 2019-2025 | |
| Astellas Pharma US INC | $174.26 | 2019-2024 | Veozah |
| Abbvie INC. | $139.82 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.05 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $110.62 | 2019-2025 | Trelegy Ellipta |
| Exact Sciences Corporation | $99.61 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $99.60 | 2019-2025 | Evenity, Prolia |
| Abbott Laboratories | $97.02 | 2023-2025 | Freestyle Libre 3, Freestyle Insulinx, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $75.45 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $71.21 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $69.81 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $48.87 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $29.50 | 2022 | |
| Amarin Pharma, INC. | $26.82 | 2020 | |
| Rgh Enterprises LLC | $22.00 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $21.76 | 2023 | Rexulti |
| Currax Pharmaceuticals LLC | $16.68 | 2025 | Contrave |
| Mylan Specialty L.P. | $16.62 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $15.94 | 2024 | Eliquis |
| Seqirus USA INC | $15.47 | 2025 | Fluad, Flucelvax |
| Corcept Therapeutics | $15.00 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.72 | 2020 | |
| Arbor Pharmaceuticals, INC. | $13.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rama Mulpuri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.